332 related articles for article (PubMed ID: 25741818)
1. Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates.
Burns KE; Robinson MK; Thévenin D
Mol Pharm; 2015 Apr; 12(4):1250-8. PubMed ID: 25741818
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models.
Burns KE; Hensley H; Robinson MK; Thévenin D
Mol Pharm; 2017 Feb; 14(2):415-422. PubMed ID: 28048942
[TBL] [Abstract][Full Text] [Related]
3. Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors.
Wyatt LC; Moshnikova A; Crawford T; Engelman DM; Andreev OA; Reshetnyak YK
Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2811-E2818. PubMed ID: 29507241
[TBL] [Abstract][Full Text] [Related]
4. pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1.
Yu M; Chen Y; Wang Z; Ding X
Breast Cancer Res Treat; 2020 Apr; 180(2):379-384. PubMed ID: 32034579
[TBL] [Abstract][Full Text] [Related]
5. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases.
Yap ML; McFadyen JD; Wang X; Ziegler M; Chen YC; Willcox A; Nowell CJ; Scott AM; Sloan EK; Hogarth PM; Pietersz GA; Peter K
Theranostics; 2019; 9(4):1154-1169. PubMed ID: 30867822
[No Abstract] [Full Text] [Related]
6. Divalent Cations and Lipid Composition Modulate Membrane Insertion and Cancer-Targeting Action of pHLIP.
Vasquez-Montes V; Gerhart J; Thévenin D; Ladokhin AS
J Mol Biol; 2019 Dec; 431(24):5004-5018. PubMed ID: 31689432
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Evaluation of Radioiodine-Labeled pH (Low) Insertion Peptide Variant 7-Like Peptide as a Noninvasive Tumor Microenvironment Imaging Agent in a Mouse MDA-MB-231 Triple-Negative Breast Cancer Model.
Wu F; Chen Y; Li D; Wang Z; Yu M
Mol Imaging Biol; 2022 Aug; 24(4):570-579. PubMed ID: 35006491
[TBL] [Abstract][Full Text] [Related]
8. Ku80-Targeted pH-Sensitive Peptide-PNA Conjugates Are Tumor Selective and Sensitize Cancer Cells to Ionizing Radiation.
Kaplan AR; Pham H; Liu Y; Oyaghire S; Bahal R; Engelman DM; Glazer PM
Mol Cancer Res; 2020 Jun; 18(6):873-882. PubMed ID: 32098827
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effect of pHLIP-amanitin.
Moshnikova A; Moshnikova V; Andreev OA; Reshetnyak YK
Biochemistry; 2013 Feb; 52(7):1171-8. PubMed ID: 23360641
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic modeling reveals parameters that govern tumor targeting and delivery by a pH-Low Insertion Peptide (pHLIP).
Svoronos AA; Engelman DM
Proc Natl Acad Sci U S A; 2021 Jan; 118(1):. PubMed ID: 33443162
[TBL] [Abstract][Full Text] [Related]
11. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
[TBL] [Abstract][Full Text] [Related]
12. Comparison of lipid-dependent bilayer insertion of pHLIP and its P20G variant.
Vasquez-Montes V; Gerhart J; King KE; Thévenin D; Ladokhin AS
Biochim Biophys Acta Biomembr; 2018 Feb; 1860(2):534-543. PubMed ID: 29138065
[TBL] [Abstract][Full Text] [Related]
13. Noncanonical amino acids to improve the pH response of pHLIP insertion at tumor acidity.
Onyango JO; Chung MS; Eng CH; Klees LM; Langenbacher R; Yao L; An M
Angew Chem Int Ed Engl; 2015 Mar; 54(12):3658-3663. PubMed ID: 25650762
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide.
Svoronos AA; Bahal R; Pereira MC; Barrera FN; Deacon JC; Bosenberg M; DiMaio D; Glazer PM; Engelman DM
Mol Pharm; 2020 Feb; 17(2):461-471. PubMed ID: 31855437
[TBL] [Abstract][Full Text] [Related]
15. Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer.
Chung SW; Cho YS; Choi JU; Kim HR; Won TH; Kim SY; Byun Y
Biomaterials; 2019 Feb; 192():109-117. PubMed ID: 30447398
[TBL] [Abstract][Full Text] [Related]
16. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
17. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels.
Temming K; Meyer DL; Zabinski R; Dijkers EC; Poelstra K; Molema G; Kok RJ
Bioconjug Chem; 2006; 17(6):1385-94. PubMed ID: 17105215
[TBL] [Abstract][Full Text] [Related]
19. pH-Selective Cytotoxicity of pHLIP-Antimicrobial Peptide Conjugates.
Burns KE; McCleerey TP; Thévenin D
Sci Rep; 2016 Jun; 6():28465. PubMed ID: 27334357
[TBL] [Abstract][Full Text] [Related]
20. Cyclic RGD-Peptide-Functionalized Polylipopeptide Micelles for Enhanced Loading and Targeted Delivery of Monomethyl Auristatin E.
Qiu M; Wang X; Sun H; Zhang J; Deng C; Zhong Z
Mol Pharm; 2018 Nov; 15(11):4854-4861. PubMed ID: 30259747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
